112
Participants
Start Date
January 10, 2023
Primary Completion Date
March 28, 2025
Study Completion Date
March 28, 2025
Nab-paclitaxel
Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
Gemcitabine
Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
VCN-01
VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
Weill Cornell Medical Center, New York
Virginia Cancer Specialists, Fairfax
Hospital Gregorio Marañon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Hospital Universitario Marqués de Valdecilla, Santander
University of Louisville - Brown Cancer Center, Louisville
Hospital Universitario Virgen del Rocío, Seville
Martha Morehouse Tower, Columbus
Hospital General Univesitario de Valencia, Valencia
Hospital Miguel Servet, Zaragoza
Huntsman Cancer Institute, University of Utah, Salt Lake City
Hoag Memorial Hospital Presbyterian, Newport Beach
University of California - Davis Cancer Center, Sacramento
Hospital Duran i Reynals (ICO), L'Hospitalet de Llobregat
Hospital Universitari Vall d'Hebron, Barcelona
Theriva Biologics SL
INDUSTRY